Page last updated: 2024-09-03

tazobactam and Urinary Tract Infections

tazobactam has been researched along with Urinary Tract Infections in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.45)	18.2507
2000's	5 (9.09)	29.6817
2010's	35 (63.64)	24.3611
2020's	12 (21.82)	2.80

Authors

Authors	Studies
Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P	1
Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH	1
Belley, A; Kaye, KS; Velicitat, P	1
Hsu, CK; Lai, CC; Tsai, WW	1
Cao, Y; Liu, C; Ren, H; Shang, Z; Wang, R; Xie, L; Yang, Y; Zhang, J	1
Chen, YH; Cheng, IL; Lai, CC; Tang, HJ	1
Dorn, C; Eberl, S; Nussbaumer-Pröll, AK; Reiter, B; Stimpfl, T; Zeitlinger, M	1
Buonomo, AR; Gentile, I; Maraolo, AE; Mazzitelli, M; Torti, C; Trecarichi, EM	1
Alves, V; Cantón, R; Chaves, C; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Melo-Cristino, J; Paixão, L; Pássaro, L; Pinto, MF; Ramalheira, E; Sancho, L; Silva, D; Vieira, AR	1
Abou Chakra, M; Dellis, A; Moussa, M; Moussa, Y; Papatsoris, A	1
Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L	1
Murri, R; Sacco, E	1
Huntington, JA; Long, J; Popejoy, MW	1
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y	1
Ali, I; Shabbir, M	1
Bodro, M; Fresco, L; Marco, F; Martínez, JA; Paredes, S; Soriano, A; Xipell, M	1
Bischoff, S; Ebert, M; Gerigk, M; Vogelmann, R; Walter, T	1
Fridrichová, M; Jakubů, V; Žemličková, H	1
Bassetti, M; De Rosa, FG; Del Bono, V; Giacobbe, DR; Grossi, PA; Menichetti, F; Pea, F; Rossolini, GM; Tumbarello, M; Viale, P; Viscoli, C	1
Bertrand, X; Bouiller, K; Bouxom, H; Fournier, D; Hocquet, D	1
Caro, L; Huntington, JA; Long, J; Xiao, AJ	1
Ang, JY; Arrieta, AC; Bradley, JS; Caro, L; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yang, S; Yu, B	1
Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A	1
Aoyama, N; Arakawa, S; Fujimoto, G; Kawahara, K; Kawahara, M; Rhee, EG; Sato, A; Yasuda, M; Yokokawa, R; Yoshinari, T	1
Feng, HP; Kakara, M; Larson, K; Rizk, ML; Shiomi, M; Yoshitsugu, H	1
Harris, PNA	1
Bradley, JS; Caro, L; Larson, KB; Patel, YT; Rhee, EG; Rizk, ML; Willavize, S	1
Chen, GJ; Chen, WT; Foo, J; Morel, C; Pan, SC; Wang, JT	1
López-Cerero, L; Muniain, MA; Pascual, Á; Retamar, P; Rodríguez-Baño, J	1
Chhibba, A; Nayak, U; Patankar, M; Sequeira, L; Sukumaran, S	1
Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K	1
Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS	1
Bassetti, M; Righi, E	1
Darouiche, RO; Steenbergen, J; Umeh, O; Wagenlehner, FM; Yuan, G	1
Chahine, EB; Cogan, P; Fete, M; Sucher, AJ	1
Geerlings, SE; Holleman, F; Schneeberger, C	1
Scott, LJ	1
Bliss, C; Cloutier, DJ; Goldstein, EJ; Huntington, JA; Sakoulas, G; Steenbergen, JN; Umeh, O	1
Alidjanov, JF; Wagenlehner, FM	1
Borgia, G; Gentile, I; Maraolo, AE	1
Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O	1
Armstrong, ES; Bliss, CA; Cloutier, DJ; Mikulca, JA; Steenbergen, JN	1
Goldstein, EJ; Kullar, R; Long, J; Popejoy, MW; Wagenlehner, FM; Yu, B	1
Hamada, Y; Nicolau, DP; Thabit, AK	1
Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA	1
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL	1
Capparelli, FJ; Del Castillo, ME; Diaz, MF; Hlavnika, A; Leiguarda, R; Wainsztein, NA	1
Ikonomidis, A; Kantzanou, M; Maniatis, AN; Neou, E; Pournaras, S; Tsakris, A	1
Arora, J; Dogra, A; Rao, P; Taneja, N	1
Nowé, P	1
Hanaki, H; Nagayama, A; Nomura, S	1
Chen, Y; Gao, L; Hou, F; Li, J	1
Naber, KG; Salmen, HC; Savov, O	1

Reviews

11 review(s) available for tazobactam and Urinary Tract Infections

Article	Year
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections. BioMed research international, 2022, Volume: 2022 Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections	2022
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials. International journal of antimicrobial agents, 2020, Volume: 55, Issue:2 Topics: Cephalosporins; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam; Urinary Tract Infections	2020
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. International journal of antimicrobial agents, 2020, Volume: 55, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Urinary Tract Infections	2020
Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:16 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Beverages; Ceftazidime; Cephalosporins; Drug Combinations; Female; Fosfomycin; Humans; Recurrence; Secondary Prevention; Tazobactam; Urinary Tract Infections; Vaccinium macrocarpon	2020
Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrobial resistance and infection control, 2021, 04-08, Volume: 10, Issue:1 Topics: Cephalosporins; Comorbidity; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections	2021
Ceftolozane/tazobactam: place in therapy. Expert review of anti-infective therapy, 2018, Volume: 16, Issue:4 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Off-Label Use; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2018
Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic. The Medical letter on drugs and therapeutics, 2015, Mar-02, Volume: 57, Issue:1463 Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam; Urinary Tract Infections	2015
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:9 Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Mice; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2015
Febrile urinary tract infections: pyelonephritis and urosepsis. Current opinion in infectious diseases, 2016, Volume: 29, Issue:1 Topics: Anti-Infective Agents, Urinary; Cephalosporins; Diabetes Complications; Fever; Humans; Immunocompromised Host; Levofloxacin; Penicillanic Acid; Pyelonephritis; Randomized Controlled Trials as Topic; Risk Factors; Sepsis; Tazobactam; Treatment Outcome; Urinary Tract Infections	2016
Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. Drugs, 2016, Volume: 76, Issue:2 Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Humans; Intraabdominal Infections; Multicenter Studies as Topic; Penicillanic Acid; Tazobactam; Urinary Tract Infections	2016
Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:8 Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Humans; Penicillanic Acid; Tazobactam; Urinary Tract Infections	2016

Trials

15 trial(s) available for tazobactam and Urinary Tract Infections

Article	Year
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial. The Pediatric infectious disease journal, 2023, 04-01, Volume: 42, Issue:4 Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections	2023
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam. BMC infectious diseases, 2017, 05-02, Volume: 17, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Female; Humans; Intraabdominal Infections; Levofloxacin; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections	2017
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections	2017
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. The Pediatric infectious disease journal, 2018, Volume: 37, Issue:11 Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Intraabdominal Infections; Male; Tazobactam; Urinary Tract Infections	2018
The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Male; Middle Aged; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections	2019
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Cephalosporins; Female; Humans; Intraabdominal Infections; Japan; Male; Middle Aged; Models, Statistical; Tazobactam; Urinary Tract Infections; Young Adult	2019
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet (London, England), 2015, May-16, Volume: 385, Issue:9981 Topics: Adult; Aged; Anti-Infective Agents, Urinary; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult	2015
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Double-Blind Method; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult	2016
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. The Journal of antimicrobial chemotherapy, 2017, Volume: 72, Issue:1 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult	2017
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC infectious diseases, 2016, 11-25, Volume: 16, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cephalosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Enterobacteriaceae Infections; Female; Follow-Up Studies; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Recurrence; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult	2016
Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. The Journal of antimicrobial chemotherapy, 2017, 03-01, Volume: 72, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Penicillanic Acid; Renal Insufficiency; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult	2017
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:5 Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections	2003
Piperacillin/tazobactam in complicated urinary tract infections. Intensive care medicine, 1994, Volume: 20 Suppl 3 Topics: Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Recurrence; Remission Induction; Tazobactam; Urinary Tract Infections	1994
A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections. Chinese medical journal, 1998, Volume: 111, Issue:11 Topics: Adolescent; Adult; Anti-Bacterial Agents; Clavulanic Acid; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Respiratory Tract Infections; Tazobactam; Ticarcillin; Urinary Tract Infections	1998
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. International journal of antimicrobial agents, 2002, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Cilastatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Pyelonephritis; Sample Size; Tazobactam; Thienamycins; Urinary Tract Infections	2002

Other Studies

29 other study(ies) available for tazobactam and Urinary Tract Infections

Article	Year
Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply. JAMA, 2023, 02-28, Volume: 329, Issue:8 Topics: Cefepime; Humans; Piperacillin; Pyelonephritis; Tazobactam; Urinary Tract Infections	2023
Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis. JAMA, 2023, 02-28, Volume: 329, Issue:8 Topics: Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Piperacillin; Pyelonephritis; Tazobactam; Urinary Tract Infections	2023
Characteristics of and antibiotic resistance in urinary tract pathogens isolated from patients with upper urinary tract stones. Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:1 Topics: Aged; Amikacin; Anti-Bacterial Agents; Cefoperazone; Drug Resistance, Bacterial; Drug Resistance, Microbial; Escherichia coli; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Sulbactam; Tazobactam; Urinary Calculi; Urinary Tract; Urinary Tract Infections	2023
Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections. The Journal of antimicrobial chemotherapy, 2020, 03-01, Volume: 75, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections	2020
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study. International journal of antimicrobial agents, 2020, Volume: 55, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intensive Care Units; Intraabdominal Infections; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections	2020
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections? Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:11 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2021
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult	2017
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa. Journal of global antimicrobial resistance, 2018, Volume: 13 Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Tazobactam; Urinary Tract Infections	2018
Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC infectious diseases, 2018, 01-26, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Female; Fluoroquinolones; Gentamicins; Germany; Humans; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Risk Factors; ROC Curve; Tazobactam; Urinary Tract Infections	2018
[Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016]. Klinicka mikrobiologie a infekcni lekarstvi, 2017, Volume: 23, Issue:4 Topics: Anti-Infective Agents, Urinary; Cephalosporins; Czech Republic; Drug Resistance, Bacterial; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections	2017
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae? International journal of antimicrobial agents, 2018, Volume: 52, Issue:1 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Urinary Tract Infections	2018
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection. International journal of antimicrobial agents, 2018, Volume: 52, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2018
NICE Guidance - Complicated urinary tract infections: ceftolozane/tazobactam: © NICE (2016) Complicated urinary tract infections: ceftolozane/tazobactam. BJU international, 2018, Volume: 121, Issue:6 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Costs; Drug Resistance, Multiple, Bacterial; Evidence-Based Medicine; Humans; Infusions, Intravenous; Patient Safety; Powders; Practice Guidelines as Topic; Risk Factors; Tazobactam; Treatment Outcome; Urinary Tract Infections	2018
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. International journal of antimicrobial agents, 2019, Volume: 53, Issue:4 Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections	2019
By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract Infections? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 11-27, Volume: 69, Issue:12 Topics: Fosfomycin; Humans; Piperacillin; Pyelonephritis; Tazobactam; Urinary Tract Infections	2019
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:6 Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Tazobactam; Urinary Tract Infections; Young Adult	2019
Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2019, Volume: 52, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Gram-Negative Bacteria; Humans; Middle Aged; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Taiwan; Tazobactam; Time Factors; Treatment Outcome; Urinary Tract Infections; Young Adult	2019
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cohort Studies; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Treatment Outcome; Urinary Tract Infections	2013
Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections. The Journal of the Association of Physicians of India, 2012, Volume: 60 Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporin Resistance; Disk Diffusion Antimicrobial Tests; Drug Combinations; Humans; India; Penicillanic Acid; Respiratory Tract Infections; Sulbactam; Tazobactam; Urinary Tract Infections	2012
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement. The Journal of antibiotics, 2014, Volume: 67, Issue:2 Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections	2014
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). The Journal of infection, 2014, Volume: 69, Issue:3 Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Citrobacter; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Europe; Gram-Negative Aerobic Bacteria; Humans; Intraabdominal Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Proteus mirabilis; Pseudomonas aeruginosa; Serratia; Tazobactam; United States; Urinary Tract Infections	2014
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections. Future microbiology, 2015, Volume: 10, Issue:2 Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Investigational New Drug Application; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome; Urinary Tract Infections	2015
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert review of anti-infective therapy, 2016, Volume: 14, Issue:10 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2016
Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Jan-01, Volume: 74, Issue:1 Topics: Anti-Bacterial Agents; Cephalosporins; Chemistry, Pharmaceutical; Drug Incompatibility; Excipients; Glucose; Humans; Infusions, Intravenous; Injections, Intravenous; Nephelometry and Turbidimetry; Penicillanic Acid; Sodium Chloride; Solubility; Tazobactam; Urinary Tract Infections	2017
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections	2017
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology, 2005, Dec-13, Volume: 65, Issue:11 Topics: Aged, 80 and over; Anti-Bacterial Agents; Brain; Cefepime; Cefixime; Cephalosporins; Confusion; Consciousness Disorders; Delirium; Epididymitis; Humans; Kidney; Male; Metabolic Clearance Rate; Neurotoxicity Syndromes; Penicillanic Acid; Piperacillin; Recovery of Function; Secondary Prevention; Systemic Inflammatory Response Syndrome; Tazobactam; Urinary Tract Infections; Withholding Treatment	2005
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:3 Topics: Adult; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2008
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. The Indian journal of medical research, 2008, Volume: 127, Issue:1 Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Humans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Urinary Tract Infections	2008
Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:2 Topics: Ampicillin; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Retrospective Studies; Sulbactam; Tazobactam; Ticarcillin; Urinary Tract; Urinary Tract Infections	1997